Exelixis has decided to discontinue development of its tissue factor-targeting antibody-drug conjugate, XB002, after assessing it unlikely to outperform Pfizer and Genmab’s Tivdak

XB002 was being tested in the Phase 1 JEWEL-101 trial for advanced solid tumors, but Exelixis will not disclose the data until a later date

Resources from XB002 will be redirected to the development of zanzalintinib, a late-stage tyrosine kinase inhibitor, the Phase 1 USP1 inhibitor XL309, and other projects in Exelixis’ pipeline

Despite halting XB002, Exelixis continues to pursue ADCs, with XB371—a TF-targeting ADC with a topoisomerase payload—still in preclinical development